Efficacy and Predictive Factors of Oral Spironolactone Treatment in Chronic Central Serous Chorioretinopathy

Table 1

Visual acuity and imaging data during the follow-up of patients with chronic CSC treated with spironolactone.

	Baseline	1 month	3 months	6 months
Complete resolution of SRF, n (%)		4 (9.5%)	20 (47.6%)	24 (57.1%%)
BCVA (logMAR) (decimal equivalent)	0.22 ± 0.27	0.21 ± 0.27	0.13 ± 0.30^†	0.13 ± 0.25
	0.6 ± 0.5	0.6 ± 0.5	0.7 ± 0.5	0.7 ± 0.6
SRF area (mm^2)	0.42 ± 0.25	0.20 ± 0.15^†	0.12 ± 0.17^†	0.07 ± 0.10^†
CMT (μm)	379.31 ± 98.40	290.77 ± 72.45	247.77 ± 88.21	223.03 ± 57.92
SFCT (μm)	439.75 ± 125.63	368.13 ± 121.89	343.97 ± 104.24	349.09 ± 104.21
CCD (%) of fellow eyes	7.16 ± 3.88	7.01 ± 2.41	6.82 ± 1.64	6.88 ± 2.45
Sattler + Haller density (%)	5.83 ± 3.12	4.94 ± 2.18	4.96 ± 2.15	4.93 ± 1.88

CSC, central serous chorioretinopathy; SRF, subretinal fluid; BCVA, best-corrected visual acuity; CMT, central macular thickness; SFCT, subfoveal choroidal thickness; CCD, choriocapillaris density. ^† compared to baseline using the Wilcoxon paired signed-rank test. during the whole follow-up period according to repeated measure analysis of variance.